Which criteria should be used for starting pharmacologic therapy for management of gestational diabetes in pregnancy? Evidence from randomized controlled trials
The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
Introduction: There is inconclusive evidence to support any specific criteria for starting pharmacologic therapy after diet in women with gestational diabetes mellitus (GDM). We aimed to analyze the most used criteria for starting pharmacologic treatment for patients with GDM.Material and methods: Electronic databases were searched from their inception to September 2017. We included all the randomized controlled trials (RCTs) of GDM managed initially by diet and exercise reporting criteria for starting pharmacologic therapy. RCTs in women with pregestational diabetes were excluded. Data regarding glucose values used for starting pharmacologic therapy were extracted and carefully reviewed.Results: We included 15 RCTs (4307 women) in the meta-analysis. For fasting glucose target, 8/14 (57%) used a value lower or equal to 90 mg/dL and the remainder used values <99 mg/dL. Of the 10 RCTs targeting 2-h postprandial values, the majority (9/10, 90%) used 120 mg/dL. The majority of RCTs (13/15, 87%) recommended pharmacologic therapy if either 1 or 2 values per 1- or 2-week period were higher than the target values: 7/13 (54%) used 1 value and 6/13 (46%) used 2 values higher than target values. One RCT (7%) used >50% of the values higher than the target values and another one (7%) used >30%.Conclusion: The majority of RCTs (87%) used very tight criteria of either 1 or 2 values over the target values in the 1 or 2-week period for starting pharmacologic treatment for patients with GDM; more than 50% used 2 values.Key MessagePharmacologic therapy should be considered in women with gestational diabetes when, despite an adequate diet and exercise, 1 or 2 blood glucose values are over the target values of 90mg/dL fasting or 120mg/dL 2-hour postprandial over 1 or 2 weeks.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The HAPO study showed that increasing glycemia is associated with increased neonatal adverse outcomes such as macrosomia, neonatal hypoglycemia, and cesarean delivery.64,115–119”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [116]
Citations
Cites
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902430 · Cited by 2,122 · cited 5×
“Fourteen out of 15 (93%) RCTs used fasting glucose as a target [1–5,7–15], the higher fasting value allowed was 99mg/dL: 8/14 (57%) used a value lower or equal to 90mg/dL as target [1–4,9,10,12,15], 5 (36%) used 95mg/dL [7,8,11,13,14], and 1 (7%) used 99mg/dL [5].”
BackgroundMethodInfluentialBasics of meta‐analysis: I 2 is not an absolute measure of heterogeneity
Borenstein, M., Higgins, J. P. T., Hedges, L. V., & Rothstein, H. R. (2017) · Research Synthesis Methods · doi:10.1002/jrsm.1230 · Cited by 1,848
Bantle (2008) · doi:10.2337/dc08-s061 · Cited by 1,795
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 3×
“Regarding the glucose values used for starting pharmacologic therapy after diet and exercise, there were seven different criteria that the included studies applied: Thirteen trials (87%) used 1 or 2 values higher than the target values [1,2,4–13,15]; of these, 7/13 (54%) used 1 value higher than target values [2,6,7,9…”
BackgroundMethodHod, M., Kapur, A., Sacks, D. A., Hadar, E., Agarwal, M., Di Renzo, G. C., Roura, L. C., McIntyre, H. D., Morris, J. L., & Divakar, H. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(15)30033-3 · Cited by 767 · cited 1×
“fails to achieve glucose control, metformin, glyburide, or insulin should be considered as safe and effective treatment options for GDM [54].”
BackgroundPractice Bulletin No. 137: Gestational Diabetes Mellitus
(2013) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000433006.09219.f1 · Cited by 581
Research works printed but not linked: 10
- Mesdaghinia E, 2013, Int J Prev Med, 4, 327
- Cypryk K, 2004, Med Sci Monit, 10, 29
- Hassan JA, 2012, Pak J Med Sci, 28, 384
- Mirzamoradi M, 2015, Acta Med Iran, 53, 97
- Refuerzo JS, 2015, Am J Perinatol, 30, 163
- Thompson DJ, 1990, Obstet Gynecol, 75, 960
- Waheed S, 2013, J Coll Physicians Surg Pak, 23, 866
- 2015, International Diabetes Federation, Atlas I
- Saccone G, J Matern Fetal Neonatal Med, 1
- Brown J, 2017, Cochrane Database Syst Rev, 11, CD012037
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Saccone, G., Khalifeh, A., Al-Kouatly, H. B., Sendek, K., & Berghella, V. (2020) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2018.1519543 · Cited by 49
Self-citationTratamento farmacológico do diabetes na gestação
Zajdenverg, L., Dualib, P. M., Lauand, T. C. G., Reichelt, A. J., Satler, F., Façanha, C. F. S., Golbert, A., Negrato, C. A., Araújo, C. A. R., & Bertoluci, M. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-13 · Cited by 48
Insulin Management for Gestational and Type 2 Diabetes in Pregnancy
Valent, A. M., & Barbour, L. A. (2024) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005640 · Cited by 16
Berghella, V., Caissutti, C., Saccone, G., & Khalifeh, A. (2019) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.01.231 · Cited by 13
Self-citation
Metadata
- Authors
- Caissutti, C., Saccone, G., Khalifeh, A., Mackeen, A. D., Lott, M., & Berghella, V.
- Affiliations
- University of Udine (IT)
- University of Naples Federico II (IT)
- Thomas Jefferson University (US)
- Geisinger Medical Center (US)
- Corresponding author
- Berghella, Vincenzo
- Venue
- The Journal of Maternal-Fetal & Neonatal Medicine
- Publisher
- Informa UK Limited
- Published
- 2018-03-20
- Volume
- 32
- Issue
- 17
- Pages
- 2905-2914
- ISSN
- 1476-4954 (ISSN-L)
- 1476-7058
- OpenAlex
- W2792561718
- Cited by
- 13
- References
- 69
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 1
- FWCI
- 0.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Maternal-Fetal & Neonatal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- gestational diabetes mellitus, treatment thresholds, 2-hour postprandial glucose, glycemic control, randomized controlled trials
- MeSH terms
- Blood Glucose, Female, Glucose Tolerance Test, Humans, Pregnancy, Randomized Controlled Trials as Topic, Diabetes, Gestational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Which criteria should be used for starting pharmacologic therapy for management of gestational diabetes in pregnancy? Evidence from randomized controlled trials. https://app.cochat.ai/papers/10.1080/14767058.2018.1449203
- The paper
- Caissutti, C., Saccone, G., Khalifeh, A., Mackeen, A. D., Lott, M., & Berghella, V. (2019). Which criteria should be used for starting pharmacologic therapy for management of gestational diabetes in pregnancy? Evidence from randomized controlled trials. The Journal of Maternal-Fetal & Neonatal Medicine. https://doi.org/10.1080/14767058.2018.1449203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.